# Table of contents

* [ğŸ’¡ The Decentralized FDA DAO](README.md)
* [ğŸ“œ Whitepaper](constitution/README.md)
  * [â˜  Problems in Clinical Research](constitution/1-introduction-and-challenges.md)
  * [ğŸ“– References](constitution/12-references.md)
  * [ğŸ’¡ Solution](constitution/2-solution.md)
  * [ğŸª™ Tokenomics](constitution/6-tokenomics.md)
* [ğŸŒ Cost Savings from Decentralized Clinical Trials](cost-savings-from-decentralized-clinical-trials.md)
* [ğŸ‘€ Lower Costs of Validated Observational Research for Efficacy](lower-costs-of-validated-observational-research-for-efficacy.md)
* [ğŸ’¡ Impact of Innovative Medicines on Life Expectancy](impact-of-innovative-medicines-on-life-expectancy.md)
* [ğŸ§ Greater Competitive Innovation and Fewer Monopolies](greater-competitive-innovation-and-fewer-monopolies.md)
* [ğŸ”® Pre-Determining Clinical Endpoints Requires Psychic Powers](pre-determining-clinical-endpoints-requires-psychic-powers.md)
* [ğŸ­ More Cures and Less Lifelong Attempts at Masking Symptoms](more-cures-and-less-lifelong-attempts-at-masking-symptoms.md)
